Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
117 hedge funds and large institutions have $785M invested in Acceleron Pharma in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 24 reducing their positions, and 17 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 24
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2% more funds holding
Funds holding: 115 → 117 (+2)
18% less capital invested
Capital invested by funds: $956M → $785M (-$171M)
36% less call options, than puts
Call options by funds: $3.25M | Put options by funds: $5.1M
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$7.84M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$4.2M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$4.05M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.75M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$18.1M |
| 2 |
PVMCI
Polaris Venture Management Co IV
Boston,
Massachusetts
|
-$16.4M |
| 3 |
ICAP
Independence Capital Asset Partners
Denver,
Colorado
|
-$13.8M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$13.6M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$7M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$392K | -10,300 | Closed |
|
|
GP
127
GLG Partners
London,
United Kingdom
| – | -$265K | -6,973 | Closed |
|
128
Group One Trading
Chicago,
Illinois
| – | -$209K | -6,479 | Closed |
|
|
CCMH
129
Cornerstone Capital Management Holdings
New York
| – | -$198K | -5,200 | Closed |
|
|
PG
130
PEAK6 Group
Chicago,
Illinois
| – | -$190K | -4,979 | Closed |
|
131
Creative Planning
Overland Park,
Kansas
| – | -$86K | -2,247 | Closed |
|
132
Simplex Trading
Chicago,
Illinois
| – | -$70.2K | -2,175 | Closed |
|
|
TRCT
133
Tower Research Capital (TRC)
New York
| – | -$32K | -831 | Closed |
|
|
SSG
134
Summit Securities Group
New York
| – | -$15K | -401 | Closed |
|
XLRN Hedge Fund Activity: Q2 2015 in Review
117 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2015, worth a combined $785M — down 18% from $956M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new XLRN positions and 17 closed out — a net gain of 2 holders — while 57 added to existing stakes and 24 trimmed.
The largest buyer was Oak Ridge Investments, adding an estimated $7.84M. The largest seller was PointState Capital, exiting entirely with an estimated $18.1M sold.
- 117 institutional investors held Acceleron Pharma (XLRN) as of Q2 2015, up from 115 in Q1 2015.
- Funds reported $785M of Acceleron Pharma stock for Q2 2015, down 18% quarter-over-quarter.
- 19 funds opened new Acceleron Pharma positions in Q2 2015 and 17 closed out, a net change of +2 holders.
- The largest Acceleron Pharma buyer in Q2 2015 was Oak Ridge Investments, an estimated $7.84M added.
- The largest Acceleron Pharma seller in Q2 2015 was PointState Capital, an estimated $18.1M sold.
Based on aggregated 13F filings for Q2 2015.